Physician profile
Robert N Stark, JR.
NPI 1427035484
$9,946.44
in general payments reported to CMS, 2019-2025
58 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,186 · 2020: $1,361 · 2021: $790 · 2022: $1,184 · 2023: $1,812 · 2024: $1,459 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,425.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,031.93 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Harmony Biosciences LLC | $928.20 | 2020 | |
| Abbott Laboratories | $903.26 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $812.10 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $785.56 | 2019-2025 | |
| Abbvie INC. | $578.89 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $536.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $533.23 | 2019-2023 | Breztri, Farxiga |
| Lilly USA, LLC | $464.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $321.15 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $263.74 | 2021-2024 | |
| Astellas Pharma US INC | $263.52 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.51 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $204.18 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $186.54 | 2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.